Y-mAbs Therapeutics Inc Q1 2024 Earnings Call Transcript Highlights Navigating ...

YMAB Stock  USD 5.19  0.37  6.65%   
About 79 percent of Y MAbs' investors are selling. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that quite a large number of traders are terrified. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
U.S. DANYELZA Net Product Sales 18.6 million, up 11 percent from Q1 2023.Global DANYELZA Net Product Sales 19.4 million, down 4 percent from Q1 2023.Total Net Product Re

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

Y MAbs Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Y MAbs Fundamental Analysis

We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Book Value Per Share

Book Value Per Share Comparative Analysis

Y MAbs is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Y mAbs Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.

Peers

Y MAbs Related Equities

STROSutro Biopharma   0.00   
0.0%
PCVXVaxcyte   0.00   
0.0%
SNDXSyndax Pharmaceuticals   1.02   
8.0%
EWTXEdgewise Therapeutics   2.45   
19.0%
MIRMMirum Pharmaceuticals   3.32   
26.0%
MRUSMerus BV   3.44   
27.0%
BLUEBluebird Bio   4.90   
39.0%
BDTXBlack Diamond   4.98   
39.0%
KRONKronos Bio   5.61   
44.0%
RVMDRevolution Medicines   5.89   
46.0%
ARQTArcutis Biotherapeutics   6.28   
50.0%
ERASErasca   6.57   
52.0%
GBIOGeneration Bio   6.90   
55.0%
ZNTLZentalis Pharmaceuticals   7.25   
57.0%
TVTXTravere Therapeutics   7.48   
59.0%
MRSNMersana Therapeutics   7.69   
61.0%
PASGPassage Bio   7.69   
61.0%
DAWNDay One   8.94   
71.0%
CCCCC4 Therapeutics   11.44   
91.0%
LRMRLarimar Therapeutics   12.54   
100.0%

Complementary Tools for YMAB Stock analysis

When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges